The fundamental philosophy of the Network Genomic Medicine (NGM) is to conduct comprehensive diagnostics in any patient with a non-resectable lung tumor that clarifies all aspects of possible treatment decisions promptly and irrespective of the question of reimbursement. The participation of the attending physician and the patient in the integrated care is a prerequisite for this.
The costs for the molecular pathological diagnosis and a second opinion are covered by the health insurer for patients of the AOK Rheinland / Hamburg as part of an integrated care contract (IV) since 01.04.2014.
In 2016 more health insurance companies cover the full cost of molecular diagnostics and second opinion within the framework of the integrated care. In patients with other health insurers, the network center requests reimbursement for the individual case, so that all costs will be covered in accordance with the IV contract / standard fee.